CCM
ALGS icon

CAAS Capital Management’s Aligos Therapeutics ALGS Stock Holding History

CAAS Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-400
Closed -$277K – 1137
2020
Q4 		$277K Buy
+400
New +$195K ﹤0.01% 733

Other funds holding ALGS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

CAAS Capital Management's ALGS Position: Q1 2021 in Review

CAAS Capital Management sold out of Aligos Therapeutics (ALGS) in Q1 2021, closing a stake of 400 shares — an estimated $277K sold.

CAAS Capital Management first reported a position in ALGS in Q4 2020 and held it in 1 quarter. The position peaked at $277K in Q4 2020. 52 funds tracked by Wall St. Rank hold ALGS as of Q1 2021.

  • CAAS Capital Management reported no remaining Aligos Therapeutics position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 400 Aligos Therapeutics shares in Q1 2021, an estimated $277K.
  • CAAS Capital Management first reported a position in Aligos Therapeutics in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Aligos Therapeutics position peaked at $277K in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.